Acquisitions, Regulatory Filings, New Community Resource Centers and Successful Clinical Trials- Research Report on Baxter, Endo, HCA, Elan, and Theravance

NEW YORK, September 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Endo Health Solutions Inc. (NASDAQ: ENDP), HCA Holdings Inc. (NYSE: HCA), Elan Corporation plc (ADR) (NYSE: ELN), and Theravance Inc. (NASDAQ: THRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Baxter International Inc. Research Report

On September 6, 2013, Baxter International Inc. (Baxter) announced its successful acquisition of Gambro AB., a privately held global medical technology company and leader in dialysis products. Baxter said that now with a broad and complementary dialysis product portfolio and global footprint, it can accelerate product sales in established markets such as Europe, where Gambro has extensive presence. The Company also plans to expand Gambro's reach in high-growth regions of Latin America and the Asia Pacific, where Baxter has steadily grown its peritoneal dialysis (PD) business. In addition, the Company said that it will build upon its core portfolio and pipeline of investigational hemodialysis (HD) and automated PD systems by adding Gambro's dialyzers, devices, and dialysis solutions, monitors, and acute therapies, to treat patients with serious kidney, liver, and lung conditions. Baxter reported that the total cash consideration of the transaction was approximately $3.9 billion. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/163d_BAX]

--

Endo Health Solutions Inc. Research Report

On September 5, 2013, Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Endo), announced that the US Food and Drug Administration (FDA) has accepted for review the complete response submission made by Endo to the New Drug Application (NDA) for its long acting testosterone undecanoate injection, AVEED. The Company stated that AVEED is intended for men diagnosed with hypogonadism. Ivan Gergel, Executive Vice President of Research and Development and Chief Scientific Officer of Endo, said, "We look forward to working with the FDA to complete the review process and make this treatment option available to appropriate male patients in the U.S. diagnosed with hypogonadism." The Company informed that in connection with the acceptance, FDA has assigned Endo's NDA a new Prescription Drug User Fee Act (PDUFA) action date of February 28, 2014. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/059c_ENDP]

--

HCA Holdings Inc. Research Report

On September 5, 2013, HCA Holdings Inc. (HCA) and Jason Foundation Inc. (JFI) announced that HCA has become a JFI National Community Affiliate and will establish Community Resource Centers at ten hospitals that provide adolescent behavioral health services. According to HCA, the Community Resource Centers will serve as hubs where parents, teachers, guidance counselors, students, churches, and other community organizations can get education materials and learn about training programs available through JFI. Terry Bridges, President of HCA Behavioral Health Services, said, "HCA is proud to support the Jason Foundation. This organization's mission to identify and intervene at the earliest possible moment with our youth and soldiers struggling with mental illness and suicidal thoughts, is consistent with HCA's commitment to the care and improvement of human life." The Full Research Report on HCA Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/be59_HCA]

--

Elan Corporation plc (ADR) Research Report

On September 3, 2013, Elan Corporation plc (ADR) (Elan) announced the first patient dosing in a Phase 2a study of ELND005 in Down syndrome, the most common genetic form of intellectual disability, caused by an extra copy of chromosome 21. The Study, called ELND005-DS201, will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioral measures. According to Elan, the first patient was dosed at the site of Dr. Ira Lott, Professor of Neurology and Pediatrics and Down Syndrome Expert at the University of California. Dr. Lott commented, "We are pleased to be starting this new study with ELND005. Drug development efforts in the field have been limited so far, and we look forward to studying the potential of ELND005 as a cognitive enhancer that may improve everyday functioning of adults with Down syndrome." The Full Research Report on Elan Corporation plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e996_ELN]

--

Theravance Inc. Research Report

On September 4, 2013, Theravance Inc. (Theravance) announced positive topline results from a dose-ranging 7-day crossover design Phase 2b study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA) administered once-a-day as a nebulized aqueous solution in patients with moderate to severe chronic pulmonary disease (COPD). According to the Company, TD-4208 met the primary efficacy endpoint for all six doses studied (ranging from 22mcg to 700 mcg) and demonstrated a statistically significant change versus placebo from baseline in trough FEV₁ (forced expiratory volume in one second). Theravance further revealed that the 175mcg dose was identified as the lowest that demonstrated a meaningful change in FEV₁ versus placebo at trough of 114 mL (95% CI: 76,153). The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fa70_THRX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner